Plain-English translation of NCT03928431 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether newborns delivered by cesarean section can benefit from exposure to their mother's natural vaginal and intestinal bacteria right after birth. Babies born vaginally are naturally exposed to these bacteria during delivery, but cesarean babies miss this exposure. Researchers think this may increase the risk of allergies and asthma, and they want to see if carefully introducing these bacteria to cesarean-born babies can help prevent these conditions.
Babies born by cesarean section don't get exposed to their mother's protective bacteria the way vaginally delivered babies do. Early research suggests this difference might increase the risk of allergies, asthma, and other immune problems. This trial aims to find out if restoring that natural bacterial exposure can protect cesarean-born babies from these conditions.
You likely qualify if…
You likely don't qualify if…
If you're in the cesarean treatment group, a sterile piece of gauze will be placed in your vagina 2 hours before your scheduled cesarean delivery, then carefully mixed with a sample of your own intestinal bacteria. Right after your baby is born, the study team will gently swab your baby's skin and other body areas with this gauze to expose your baby to your natural bacteria. Your baby will then be placed on your chest for skin-to-skin contact and breastfeeding. The study team will follow your baby's health and collect information about allergies and immune development until age 2, comparing results between treated cesarean babies, untreated cesarean babies, and vaginally delivered babies.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Sweden